Adrenomedullin
Phase 2Small molecule
Adrenomedullin is one of 31 small molecule programs targeting Headache. It is currently in Phase 2.
3
Indications
3
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Savella
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Cervidil
PfizerPreclinical
Adrenomedullin
DDanish Headache Center
Phase 2
Viagra
VViatris Specialty LLC
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Pristiq
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adrenomedullin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDanish Headache Center